Company: CI
Filing Date: 2025-03-14
Form Type: DEF 14A
Source: 0001739940-25-000015
Chunk: 46

Company: Cigna Group
Filing Date: 2025-03-14
Form: DEF 14A
Chunk 46
---
 of long-term value benefiting our customers, patients, clients, shareholders, and other stakeholders.

As discussed more fully in the Compensation Discussion and Analysis, the primary principles underlying our compensation philosophy are that our compensation program should motivate superior enterprise results by creating a better future built on the vitality of every individual and community; align the interests of the Company’s executives with those of our customers, patients, clients, long-term shareholders, and other stakeholders; emphasize performance-based compensation over fixed compensation while minimizing inappropriate risk-taking behaviors; incentivize long-term results more heavily than the achievement of short-term results; and provide market-competitive compensation opportunities designed to attract and retain executives who are highly qualified and dedicated to improving the health and vitality of those we serve.

In recognition of the preference of shareholders expressed at The Cigna Group 2023 annual meeting of shareholders, the Board has determined to continue to hold “say-on-pay” advisory votes on an annual basis. The next vote on the frequency of “say-on-pay” advisory votes will be held at the 2029 annual meeting of shareholders. Consistent with this practice and SEC rules, we are asking you to approve the following resolution:

| RESOLVED, that the shareholders approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Company’s Proxy Statement for the 2025 Annual Meeting of Shareholders pursuant to the compensation disclosure rules of the Securities and Exchange Commission, including the Compensation Discussion and Analysis, Executive Compensation Tables, and accompanying narrative disclosure. |

This advisory vote is intended to address our overall compensation policies and practices related to the named executive officers, rather than any specific element of compensation. In considering your vote, we encourage you to review the Proxy Statement Summary, the Compensation Discussion and Analysis, and the Executive Compensation Tables and related narrative disclosures appearing below. Because your vote is advisory, it will not be binding upon the Board. However, the Board and People Resources Committee value your opinion and will review and consider the voting results when making future executive compensation decisions.

| 51 |     | The Cigna Group| 2025 Notice of Annual Meeting of Shareholders and Proxy Statement |

| COMPENSATION MATTERS |

### Compensation Discussion and Analysis
This Compensation Discussion and Analysis (CD&A) describes the compensation policies, programs, and decisions regarding our named executive officers (NEOs) for 2024, which include our CEO, Chief Financial Officer, and the three other most highly compensated executive officers as of the end of 2024.

| David M. Cordani